Recent Updates — ZLAB

Zai Lab Limited entered into a securities purchase agreement for the private sale of 11,340,000 American Depositary Shares (ADSs) to accredited investors in a PIPE transaction priced at $22.04 per ADS. The company expects to receive approximately $250 million in gross proceeds before deducting placement agent fees and other offering expenses. The closing is expected on or about October 27, 2026, subject to customary conditions. Net proceeds will primarily support the global development of zocilurtatug pelitecan (zoci), a DLL3-targeting antibody-drug conjugate, for working capital and general corporate purposes. Zai Lab Limited is an innovation-driven biopharmaceutical company focused on discovering and commercializing products in oncology, immunology, neuroscience, and infectious disease.

Zai Lab Limited reported second quarter 2026 financial results with total revenue of $106.3 million and a net loss of $50.8 million, or $0.05 per ordinary share. Net product revenue reached $105.8 million, reflecting an 11% sequential increase driven by stabilization of ZEJULA sales and double-digit volume growth for VYVGART. The company maintains a cash position of $717.5 million as of June 30, 2026. Pipeline updates include the receipt of Orphan Drug Designation from the FDA and EMA for zocilurtatug pelitecan (zoci) in neuroendocrine carcinomas, and the commercial launch of KarXT in mainland China for schizophrenia treatment. Zai Lab operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in oncology, immunology, neuroscience, and infectious disease.